Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Decentralized derivatives protocol Synthetix officially launches perpetual contract DEX on Ethereum mainnet

Decentralized derivatives protocol Synthetix officially launches perpetual contract DEX on Ethereum mainnet

BlockBeatsBlockBeats2025/12/19 02:34
Show original

BlockBeats News, December 19, decentralized derivatives protocol Synthetix announced the launch of its perpetual contract DEX on the Ethereum mainnet, adopting a hybrid CLOB model with on-chain asset custody and off-chain matching to bypass mainnet latency and high gas costs. The first batch supports BTC, ETH, and SOL perpetual contracts, with up to 50x leverage, and plans to introduce multi-collateral margin, RWA support, and incentive programs.


The platform's market making and liquidity are provided by SLP Vault. Synthetix aims to become the first successful CLOB perp trading platform on the Ethereum mainnet.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds